Abstract
Intramyocardial injection of heart explant-derived cells (EDCs) improves cardiac function in preclinical models of ischemic cardiomyopathy. This therapeutic benefit is partially attributable to the anti-inflammatory cargo (micro RNAs and proteins) enriched within the extracellular vesicles (EVs) released by EDCs. Recent work has shown that activation of the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome in both immune and non-immune cells plays a critical role in promoting cardiac inflammation and adverse remodeling.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
